1. Search Result
Search Result
Results for "

Helicase+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Fluorescent Dyes

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-169422

    IDE275

    DNA/RNA Synthesis Cancer
    GSK4418959 (IDE275) is a selective, reversible and orally active WRN helicase inhibitor. GSK4418959 shows >10,000-fold selectivity over other helicases. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer, such as colorectal cancer (CRC) and endometrial cancer (EC) .
    GSK4418959
  • HY-100455
    RK-33
    5 Publications Verification

    DNA/RNA Synthesis SARS-CoV Cancer
    RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
    RK-33
  • HY-110185
    NSC 617145
    3 Publications Verification

    DNA/RNA Synthesis Cancer
    NSC 617145 is a selective werner syndrome helicase (WRN) helicase inhibitor with an IC50 value of 230 nM. NSC 617145 inhibits WRN ATPase, and induces double-strand breaks (DSB) and chromosomal abnormalities. NSC 617145 shows selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases .
    NSC 617145
  • HY-156418

    DNA/RNA Synthesis Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Cancer
    KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe 2+, and decreases the level of GSH in cancer cells . KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma .
    KY386
  • HY-162471

    DNA/RNA Synthesis ATM/ATR Cancer
    GSK_WRN3 is selective WRN helicase inhibitor (pIC50 = 8.6). SK_WRN3 can selectively inhibit the growth of microsatellite unstable (MSI) cancer cells, induce DNA damage, and cause cell cycle arrest. GSK_WRN3 has anti-tumor activity .
    GSK_WRN3
  • HY-163942

    DNA/RNA Synthesis Cancer
    GSK_WRN4 is an orally active WRN helicase inhibitor (pIC50=7.6). GSK_WRN4 induces DNA damage markers (p21, p-γH2AX, p-KAP1). GSK_WRN4 selectively inhibits microsatellite-unstable tumor growth in vitro and in vivo by inducing DNA double-strand breaks, particularly at expanded TA repeats and regions of DNA damage .
    GSK_WRN4
  • HY-128712

    DNA/RNA Synthesis Cancer
    NCGC00029283 is a werner syndrome helicase-nuclease (WRN) helicase inhibitor with IC50s of 2.3 μM, 12.5 μM, and 3.4 μM for WRN, BLM and FANCJ helicase, respectively .
    NCGC00029283
  • HY-169422A

    IDE275 (enantiomer)

    DNA/RNA Synthesis Cancer
    GSK4418959 enantiomer is an enantiomer of GSK4418959 (HY-169422). GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer .
    GSK4418959 (enantiomer)
  • HY-D0306

    Leucopararosaniline

    DNA/RNA Synthesis HCV Infection
    Tris(4-aminophenyl)methane is a triphenylmethane dye. Tris(4-aminophenyl)methane is a weak HCV helicase inhibitor.
    Tris(4-aminophenyl)methane
  • HY-173018

    HCV Dengue Virus Infection
    ML283 is a HCV NS3 helicase inhibitor (IC50: 2.6 μM). ML283 also inhibits DenV ATPase (IC50: 4.0 μM) .
    ML283
  • HY-178991

    DNA/RNA Synthesis Cancer
    WRN-IN-21 (Compound 11b) is a WRN helicase inhibitor with pIC50 values for WRN and BLM helicases of 3.6 and 5.4 respectively. WRN-IN-21 can be used for the study of MSI-related cancers .
    WRN-IN-21
  • HY-174217

    DNA/RNA Synthesis Cancer
    WRN-IN-19 (Compound (S)-27) is a covalent WRN helicase inhibitor, with pIC50 (0 h/4 h) = 5.4/7.5 in the DNA-unwinding 5 endpoint assays. WRN-IN-19 shows synthetic lethality in MSI-H (high microsatellite instability) cancer cells .
    WRN-IN-19
  • HY-164852

    DNA/RNA Synthesis Others
    WRN inhibitor 13 is a WRN helicase inhibitor with a pIC50 of 6-7 .
    WRN inhibitor 13
  • HY-146987

    DNA/RNA Synthesis SARS-CoV Infection
    FWM-3 is a potent SARS-CoV-2 NSP13 helicase inhibitor .
    FWM-3
  • HY-106305A

    CI 958 trihydrochloride

    DNA/RNA Synthesis Cancer
    Ledoxantrone (CI 958) trihydrochloride is a DNA helicases inhibitor with an IC50 of 0.17 μM. Ledoxantrone trihydrochloride can be used in the study of prostate cancer .
    Ledoxantrone trihydrochloride
  • HY-106305

    CI 958

    DNA/RNA Synthesis Cancer
    Ledoxantrone (CI 958) is a DNA helicases inhibitor with an IC50 of 0.17 μM. Ledoxantrone can be used in the study of prostate cancer .
    Ledoxantrone
  • HY-144798

    SARS-CoV Infection
    FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .
    FWM-5
  • HY-163941

    DNA/RNA Synthesis Cancer
    GSK_WRN2 is a potent and selective covalent WRN helicase inhibitor that suppresses replication stress caused by DNA (TA)n dinucleotide repeat expansions. GSK_WRN2 can be used to study microsatellite instability (MSI) cancers .
    GSK_WRN2
  • HY-161151

    DNA/RNA Synthesis Apoptosis Cancer
    Frangulin B (Compd 11g), a potent anticancer agent, is a potential pan RecQ helicase inhibitor . Frangulin B (Compd 11g) induces apoptosis in both HCT-116 and MDA-MB-231 cell lines, but also causes an G2/M phase cell cycle arrest in HCT-116 cells .
    RecQ helicase-IN-1
  • HY-176727

    DNA/RNA Synthesis Cancer
    WRN inhibitor 19 (Compound 40) is a WRN helicase inhibitor (IC50: 3.7 nM). WRN inhibitor 19 exhibits selective antiproliferative activity in WRN-dependent cancer cells. WRN inhibitor 19 inhibits WRN helicase function by competitively binding to the ATP site and induces DNA damage and cell cycle arrest. WRN inhibitor 19 can be used in the study of WRN-dependent cancers .
    WRN inhibitor 19
  • HY-100455R

    DNA/RNA Synthesis Reference Standards SARS-CoV Cancer
    RK-33 (Standard) is the analytical standard of RK-33 (HY-100455). This product is intended for research and analytical applications. RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.
    RK-33 (Standard)
  • HY-182634

    DNA/RNA Synthesis Phosphatase Cancer
    NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma .
    NCGC00063279
  • HY-180578

    SARS-CoV Infection
    MWAC-3429 is a potent SARS-CoV-2 Nsp13 helicase inhibitor. MWAC-3429 inhibits SARS-CoV-2 and SARS-CoV1 with EC50s of 5.39 (nLuc assay) and 17.00 μM (CPE assay), respectively, while showing low cytotoxicity in A549-hACE2 cells (CC50 > 50 μM). MWAC-3429 can be used for SARS-CoV-infection research .
    MWAC-3429
  • HY-117802

    DNA/RNA Synthesis HCV HCV Protease Infection
    CID-50930756 is an HCV NS3 helicase inhibitor with an IC50 of 22 μM.CID-50930756 inhibits HCV NS3 helicase-catalyzed nucleic acid unwinding.CID-50930756 inhibits HCV replication in hepatoma cells harboring a stably transfected subgenomic HCV replicon.CID-50930756 does not exhibit toxicity to hepatoma cells at 10 μM.CID-50930756 shows weak DNA-binding activity, displacing less than 20% of SYBR Green I from DNA at 100 μM.CID-50930756 can be used for the research of hepatitis c .
    CID-50930756

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: